Helixate FS, Mix2Vial now packaged together

Article

CSL Behring has begun packaging Helixate FS, its advanced recombinant FVIII (rFVIII) factor product for the treatment of hemophilia A, with Mix2Vial, its needle-free transfer device. The new packaging was developed in response to comprehensive market research of customers and to meet the latest OSHA requirements. For more information, visit

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.